184 related articles for article (PubMed ID: 23555626)
1. Health system barriers to access and use of magnesium sulfate for women with severe pre-eclampsia and eclampsia in Pakistan: evidence for policy and practice.
Bigdeli M; Zafar S; Assad H; Ghaffar A
PLoS One; 2013; 8(3):e59158. PubMed ID: 23555626
[TBL] [Abstract][Full Text] [Related]
2. Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia.
Ridge AL; Bero LA; Hill SR
BMC Health Serv Res; 2010 Dec; 10():340. PubMed ID: 21162717
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting use of magnesium sulphate for pre-eclampsia or eclampsia: a qualitative evidence synthesis.
Eddy KE; Vogel JP; Zahroh RI; Bohren MA
BJOG; 2022 Feb; 129(3):379-391. PubMed ID: 34520111
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing the use of magnesium sulphate in pre-eclampsia/eclampsia management in health facilities in Northern Nigeria: a mixed methods study.
Oguntunde O; Charyeva Z; Cannon M; Sambisa W; Orobaton N; Kabo IA; Shoretire K; Danladi SE; Lawal N; Sadauki H
BMC Pregnancy Childbirth; 2015 Jun; 15():130. PubMed ID: 26037906
[TBL] [Abstract][Full Text] [Related]
5. Benefits of using magnesium sulphate (MgSO₄) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria.
Okereke E; Ahonsi B; Tukur J; Ishaku SM; Oginni AB
BMC Res Notes; 2012 Aug; 5():421. PubMed ID: 22873658
[TBL] [Abstract][Full Text] [Related]
6. Clinical practice patterns on the use of magnesium sulphate for treatment of pre-eclampsia and eclampsia: a multi-country survey.
Long Q; Oladapo OT; Leathersich S; Vogel JP; Carroli G; Lumbiganon P; Qureshi Z; Gülmezoglu AM;
BJOG; 2017 Nov; 124(12):1883-1890. PubMed ID: 27885772
[TBL] [Abstract][Full Text] [Related]
7. Availability of treatment for eclampsia in public health institutions in Maharashtra, India.
Chaturvedi S; Randive B; Mistry N
J Health Popul Nutr; 2013 Mar; 31(1):86-95. PubMed ID: 23617209
[TBL] [Abstract][Full Text] [Related]
8. Maternal and fetal outcomes after introduction of magnesium sulphate for treatment of preeclampsia and eclampsia in selected secondary facilities: a low-cost intervention.
Tukur J; Ahonsi B; Ishaku SM; Araoyinbo I; Okereke E; Babatunde AO
Matern Child Health J; 2013 Sep; 17(7):1191-8. PubMed ID: 22956402
[TBL] [Abstract][Full Text] [Related]
9. Facility and personnel factors influencing magnesium sulfate use for eclampsia and pre-eclampsia in 3 Indian hospitals.
Barua A; Mundle S; Bracken H; Easterling T; Winikoff B
Int J Gynaecol Obstet; 2011 Dec; 115(3):231-4. PubMed ID: 21930268
[TBL] [Abstract][Full Text] [Related]
10. Treating patients with severe preeclampsia and eclampsia in Oaxaca, Mexico.
Van Dijk MG; García-Rojas M; Contreras X; Krumholz A; García SG; Díaz-Olavarrieta C
Salud Publica Mex; 2014; 56(5):426-7. PubMed ID: 25604285
[No Abstract] [Full Text] [Related]
11. Reducing maternal mortality from preeclampsia and eclampsia in low-resource countries--what should work?
Goldenberg RL; Jones B; Griffin JB; Rouse DJ; Kamath-Rayne BD; Trivedi N; McClure EM
Acta Obstet Gynecol Scand; 2015 Feb; 94(2):148-55. PubMed ID: 25353716
[TBL] [Abstract][Full Text] [Related]
12. Use of magnesium sulfate before 32 weeks of gestation: a European population-based cohort study.
Wolf HT; Huusom L; Weber T; Piedvache A; Schmidt S; Norman M; Zeitlin J;
BMJ Open; 2017 Jan; 7(1):e013952. PubMed ID: 28132012
[TBL] [Abstract][Full Text] [Related]
13. The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia.
Tukur J
Ann Afr Med; 2009; 8(2):76-80. PubMed ID: 19805935
[TBL] [Abstract][Full Text] [Related]
14. Availability and use of magnesium sulphate at health care facilities in two selected districts of North Karnataka, India.
Katageri G; Charantimath U; Joshi A; Vidler M; Ramadurg U; Sharma S; Bannale S; Payne BA; Rakaraddi S; Karadiguddi C; Mungarwadi G; Kavi A; Sawchuck D; Derman R; Goudar S; Mallapur A; Bellad M; Magee LA; Qureshi R; von Dadelszen P;
Reprod Health; 2018 Jun; 15(Suppl 1):91. PubMed ID: 29945665
[TBL] [Abstract][Full Text] [Related]
15. Translating research into policy and practice in developing countries: a case study of magnesium sulphate for pre-eclampsia.
Aaserud M; Lewin S; Innvaer S; Paulsen EJ; Dahlgren AT; Trommald M; Duley L; Zwarenstein M; Oxman AD
BMC Health Serv Res; 2005 Nov; 5():68. PubMed ID: 16262902
[TBL] [Abstract][Full Text] [Related]
16. Use of magnesium sulfate for treatment of pre-eclampsia and eclampsia in Mexico.
van Dijk MG; Díaz Olavarrieta C; Zuñiga PU; Gordillo RL; Gutiérrez ME; García SG
Int J Gynaecol Obstet; 2013 May; 121(2):110-4. PubMed ID: 23465851
[TBL] [Abstract][Full Text] [Related]
17. The WHO Safe Childbirth Checklist implementation: impact on the prescription of magnesium sulphate through a one-year longitudinal study.
da Silva Gama ZA; Medeiros WR; Saturno-Hernández PJ; de Meneses Sousa K; Mello MS; de Lima Vale É; de Souza Rosendo TMS; da Silva EMM; de Freitas MR
BMC Pregnancy Childbirth; 2020 Mar; 20(1):154. PubMed ID: 32164643
[TBL] [Abstract][Full Text] [Related]
18. Obstetrician's risk perception on the prescription of magnesium sulfate in severe preeclampsia and eclampsia: A qualitative study in Brazil.
Lotufo FA; Parpinelli MA; Osis MJ; Surita FG; Costa ML; Cecatti JG
PLoS One; 2017; 12(3):e0172602. PubMed ID: 28301493
[TBL] [Abstract][Full Text] [Related]
19. Magnesium sulphate in management of severe pre-eclampsia and eclampsia.
Dhakal G; Subedi M; Paudel K
J Nepal Health Res Counc; 2012 May; 10(21):113-7. PubMed ID: 23034372
[TBL] [Abstract][Full Text] [Related]
20. Maternal and perinatal outcome of severe pre-eclampsia in Enugu, Nigeria after introduction of Magnesium sulfate.
Ugwu EO; Dim CC; Okonkwo CD; Nwankwo TO
Niger J Clin Pract; 2011; 14(4):418-21. PubMed ID: 22248941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
